Management of Sulfasalazine-Induced Gastritis

The American Gastroenterological Association recommends that for patients experiencing gastritis due to sulfasalazine, switching to an alternative 5-ASA medication such as mesalamine or balsalazide is strongly recommended as these medications provide similar efficacy with fewer gastrointestinal side effects 1, 2
Sulfasalazine is associated with gastrointestinal side effects in up to 35% of patients, including nausea, vomiting, diarrhea, abdominal pain, and dyspepsia 2
The sulfapyridine moiety (not the 5-ASA component) is responsible for most adverse effects of sulfasalazine 1, 3

Management Algorithm

Replace sulfasalazine with standard-dose mesalamine (2-3g/day) or diazo-bonded 5-ASA (balsalazide), as mesalamine and balsalazide have similar efficacy to sulfasalazine but with significantly fewer GI side effects 1, 3, 4
Balsalazide is the preferred diazo-bonded 5-ASA due to better tolerability 1
Ensure folate supplementation, as sulfasalazine interferes with folate metabolism 1, 2

Monitor complete blood count and liver function tests periodically while on sulfasalazine, and assess symptom improvement within 2-4 weeks of intervention 1, 2, 5

Patients with concomitant arthritic symptoms may particularly benefit from sulfasalazine, making the management of side effects more important than immediate discontinuation 1, 2

High-quality evidence shows that standard-dose mesalamine (2-3g/day) is as effective as sulfasalazine for both induction and maintenance of remission in ulcerative colitis 4, 5
Diazo-bonded 5-ASA medications are more effective than sulfasalazine for inducing remission (RR 0.77, 95% CI 0.61-0.96) with similar effectiveness for maintenance 1
Both mesalamine and diazo-bonded 5-ASA are better tolerated than sulfasalazine in induction trials 1